Pneumocystis Pneumonia Clinical Trial
Pneumocystis Pneumonia is increasing in Immunocompromised Non-HIV Infected Patients. The effects and safety of caspofungin and corticosteroids is not certain in this population. All Immunocompromised Non-HIV patients with respiratory failure were randomized into caspofungin and non-caspofungin group and corticosteroids and non-steroids group. The major outcome is 28 day mortality, the second outcome are time of respiratory rate decreases to less than 25 breath per minute, body temperature lower than 37.3℃.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05835479 -
Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults
|
Phase 2 | |
| Recruiting |
NCT05605145 -
PCP in Immunocompromised Population in Southern China
|
||
| Completed |
NCT03087890 -
Impact of Cotrimoxazole Use in Immunocompetent HIV Patients on Carriage of Antimicrobial Resistant Bacteria
|
Phase 4 | |
| Completed |
NCT05077150 -
A Case-control Study on Risk Factors, Timing, and PCR Use, for Pneumocystis Pneumonia (PcP) After Allogeneic HSCT
|
||
| Not yet recruiting |
NCT04851015 -
Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia
|
Phase 3 | |
| Not yet recruiting |
NCT06431958 -
Droplet Digital PCR and PCR-free BIOSensors for the Detection of Resistance-associated SNPs in Pneumocystis Jirovecii
|
||
| Not yet recruiting |
NCT06442345 -
Pneumocystis Jirovecii Genotyping
|
||
| Recruiting |
NCT02550080 -
Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome
|
Phase 4 | |
| Completed |
NCT00869544 -
Pneumocystis in Pathogenesis of HIV-associated Emphysema
|
||
| Recruiting |
NCT03978559 -
Trimethoprim/Sulfamethoxazole Combined With Caspofungin as First-line Therapy in PCP
|
Phase 4 | |
| Completed |
NCT04358419 -
Non-invasive Diagnosis of Invasive Pulmonary Aspergillosis by Use of Biomarkers in Exhaled Breath Condensate
|